ArriVent BioPharma (AVBP): supplier and adviser map for investors
ArriVent BioPharma is a clinical-stage biopharmaceutical company that monetizes by advancing licensed and in‑house oncology assets toward regulatory approval and then extracting value through product sales, partnerships and follow-on equity financings. The company currently has no product revenue; it depends on licensing relationships, contract manufacturers to supply clinical and launch material, and periodic capital raises to fund operations. For a consolidated view of third‑party counterparties and how they affect enterprise risk, see https://nullexposure.com/.
Quick thesis for investors
ArriVent is a biotech sponsor with operational exposure concentrated in third‑party manufacturing and advisory relationships. The core value drivers are clinical progression of furmonertinib and ARR‑217, regulatory milestones (including recent NMPA activity for the partner Allist), and the company’s ability to secure capital on non‑dilutive or tolerable terms. Operational risk clusters in APAC manufacturing partners and single‑sourced supply agreements, while financing and banking relationships support an active public capital strategy.
Explore a detailed supplier map at https://nullexposure.com/ for decision support.
How ArriVent runs the business: contracting posture, concentration and criticality
ArriVent does not operate its own manufacturing; it relies on contract manufacturers and external service providers. According to the FY2024 10‑K, the company has executed technology transfer and expects to enter commercial supply agreements with WuXi SynTheAll (WuXi STA) and relies on Zhejiang Raybow for drug substance—signals of long‑term contracting posture with identified critical manufacturers. The 10‑K also states both primary third‑party manufacturers are located in China, creating APAC concentration while noting WuXi STA’s global footprint for potential geographic diversification. Company filings characterize suppliers as critical to trial timelines and commercialization, and ArriVent explicitly reports no redundant internal manufacturing capacity.
These features produce a familiar biopharma operating model: clinical‑stage value appreciation contingent on regulatory success, while near‑term enterprise continuity depends on external manufacturers and periodic equity capital. If you evaluate counterparty risk for operations or financings, this supplier and advisor map is foundational. For ongoing monitoring, visit https://nullexposure.com/.
Supplier, banking and advisor relationships: who shows up and what that means
Zhejiang Raybow Pharmaceutical Company, Ltd.
ArriVent has an agreement with Zhejiang Raybow to supply drug substance for furmonertinib used in ongoing and planned clinical trials, making Raybow a production partner for the lead oncology asset. (Source: ArriVent FY2024 10‑K)
WuXi SynTheAll Pharmaceutical Company, Ltd. (WuXi STA)
WuXi STA supplies drug substance and has completed technology transfer to manufacture clinical and initial commercial launch supplies of firmonertinib, positioning it as the primary contract manufacturer for both drug substance and product. (Source: ArriVent FY2024 10‑K)
WuXi XDC Cayman, Inc.
ArriVent expects to rely on WuXi XDC to manufacture ARR‑002 drug product and drug substances for initial clinical studies, indicating another WuXi group company in the manufacturing supply chain. (Source: ArriVent FY2024 10‑K)
Citigroup / Citi
Citigroup acted as a joint book‑running manager on a proposed $75 million public offering announced in 2026 and has been a bookrunner on earlier deals; Citi is part of the company’s capital markets syndicate. (Source: QuiverQuant and Mintz press coverage of the FY2025 offering)
Goldman Sachs & Co. LLC / Goldman Sachs
Goldman Sachs served as a joint book‑running manager on ArriVent’s underwritten public offering and was listed as a joint bookrunner on earlier transactions, making it a lead financing counterparty. (Source: QuiverQuant and StockTitan coverage, FY2025)
Guggenheim Securities
Guggenheim Securities is named as a joint book‑running manager on the 2026‑dated offering announcements, reinforcing the company’s use of multi‑bank syndicates for equity raises. (Source: QuiverQuant and StockTitan, FY2025)
Mintz
Mintz provided legal advisory services to ArriVent on the $75 million underwritten public offering, acting as counsel on the transaction. (Source: Mintz press release, March 2026)
The Nasdaq Global Market
ArriVent’s common stock is listed on The Nasdaq Global Market under the ticker AVBP, defining its primary exchange and liquidity venue. (Source: Mintz press release, FY2025)
Lepu Biopharma Co., Ltd. / Lepu Biopharma
ArriVent entered a collaboration with Lepu Biopharma for ARR‑217 and recorded a one‑time $40 million upfront payment in 1Q2025, indicating material cash commitment and strategic external development capacity. (Source: Globenewswire/ManilaTimes reporting and Bitget news, FY2025–FY2026)
Shanghai Allist Pharmaceutical Technology Co., Ltd. / Allist Pharmaceuticals
Furmonertinib is licensed from Allist; Allist received NMPA approval for firmonertinib in February 2026 for a specific EGFR mutation indication, which materially changes commercialization optionality and partner economics. (Source: Globenewswire 2021 licensing release and Bitget reporting on NMPA approval, FY2021 & FY2026)
Jefferies
Jefferies was a joint bookrunner on earlier deals alongside Goldman Sachs and Citi, reflecting prior capital markets relationships dating to the company’s IPO process. (Source: Renaissance Capital news on FY2024 IPO syndicate)
LifeSci Capital
LifeSci Capital acted as a lead manager on the $75 million offering with Oppenheimer, confirming the presence of specialty life‑science investors in the syndicate. (Source: Mintz and StockTitan reporting, FY2025)
Oppenheimer & Co.
Oppenheimer served as a lead manager on the 2025 offering, participating in the company’s equity placement strategy. (Source: Mintz press release, FY2025)
B. Riley Securities
B. Riley functioned as a co‑manager on the underwritten offering, rounding out the mid‑market sell‑side support. (Source: Mintz and StockTitan reporting, FY2025)
H.C. Wainwright & Co.
H.C. Wainwright is listed among co‑managers for the offering, representing a retail/healthcare‑focused placement role. (Source: Mintz press release, FY2025)
Jones
Jones acted as a co‑manager on the 2025 offering, contributing to distribution breadth for the equity raise. (Source: Mintz press release, FY2025)
Investment implications and operational risk — what investors and operators must track
- Supply chain concentration: ArriVent relies on a small set of China‑based contract manufacturers for clinical and potential commercial supply; the FY2024 10‑K frames these relationships as both active and long‑term for key assets. This creates a single‑point operational dependency that is material to development timelines and commercial readiness.
- Critical manufacturing role: The company explicitly states these relationships are critical to trial continuity and commercialization plans; any disruption to Raybow, WuXi STA or affiliated sites would have immediate programmatic consequences. (Source: ArriVent FY2024 10‑K)
- Capital reliance: ArriVent operates with no product revenue (RevenueTTM = 0) and negative EPS (Diluted EPS TTM = -4.32), relying on equity markets and syndicates (Goldman Sachs, Citi, Guggenheim et al.) to fund operations; the $75M offering and syndicate composition are recent examples. (Sources: company overview and Mintz/QuiverQuant news, FY2025)
- Corporate ownership and liquidity: Institutional ownership is high (96.36%), which supports analyst coverage (consensus target $40.44) but concentrates sell‑side influence and potential secondary supply pressure. (Source: company overview)
For operational counterparties and procurement teams, the priority actions are contract redundancy, qualification of secondary sources outside APAC, and strengthened supply‑continuity clauses in commercial supply agreements with WuXi STA and others.
If you want live updates and a supplier risk scorecard for AVBP, review our supplier intelligence hub at https://nullexposure.com/.
Bottom line for investors and operators
ArriVent’s near‑term enterprise value is directly tied to clinical progress and the integrity of a narrowly concentrated supply chain. The company has built definitive relationships with major contract manufacturers and an experienced set of bankers and legal advisors to access capital markets; however, the operational criticality of Chinese manufacturers and the company’s lack of redundant internal manufacturing are the dominant counterparty risks highlighted in filings. Monitor contract milestones with WuXi and Raybow, the Lepu collaboration economics, and any shifts in the banking syndicate as the clearest leading indicators of enterprise stability.
For further supplier mapping and to track changes in ArriVent’s counterparty network, visit https://nullexposure.com/.